Zevra Therapeutics (ZVRA) Other Operating Expenses (2016 - 2026)

Zevra Therapeutics has reported Other Operating Expenses for 10 years, with the latest figure at $43.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses changed N/A year-over-year to $43.3 million; the trailing twelve-month figure through Mar 2026 stood at $191.6 million (changed N/A YoY), and the FY2025 full-year result was $148.3 million, changed N/A from the prior year.
• Other Operating Expenses for Q1 2026 stood at $43.3 million, down from $148.3 million in the prior quarter.
• The five-year high for Other Operating Expenses was $148.3 million in Q2 2025, with the low at -$25.9 million in Q3 2023.
• Historically, Other Operating Expenses has averaged $13.6 million across 5 years, with a median of -$9.4 million in 2022.
• The largest YoY upside for Other Operating Expenses was 1671.4% in 2022 against a maximum downside of 17344.07% in 2022.
• Zevra Therapeutics' Other Operating Expenses stood at -$10.2 million in 2022, then sank by 137.0% to -$24.1 million in 2023, then grew by 14.35% to -$20.7 million in 2024, then surged by 818.21% to $148.3 million in 2025, then plunged by 70.8% to $43.3 million in 2026.
• The last three Other Operating Expenses figures came in at $43.3 million (Q1 2026), $148.3 million (Q2 2025), and -$20.7 million (Q1 2024), per Business Quant data.